220 related articles for article (PubMed ID: 31684888)
1. Parenchymal central nervous system involvement in aggressive B-cell lymphoma: retrospective analysis of clinical and MRI features in a Chinese population.
Wu Y; Wang Y; Sun X; Bai X; Qian J; Zhu H; Cui Q; Xing R; Chen Y; Liu Q; Guo J; Ji N; Sun S; Liu Y
BMC Neurol; 2019 Nov; 19(1):268. PubMed ID: 31684888
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
[TBL] [Abstract][Full Text] [Related]
3. Results of combined-modality therapy for primary and secondary malignant lymphoma of the central nervous system (CNS).
Kawamura T; Koga S; Okamoto M; Kanno T; Iwamura H
Radiat Med; 2001; 19(3):145-9. PubMed ID: 11467381
[TBL] [Abstract][Full Text] [Related]
4. Secondary central nervous system lymphoma: spectrum of morphological MRI appearances.
Malikova H; Burghardtova M; Koubska E; Mandys V; Kozak T; Weichet J
Neuropsychiatr Dis Treat; 2018; 14():733-740. PubMed ID: 29559780
[TBL] [Abstract][Full Text] [Related]
5. Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma?
Malikova H; Koubska E; Weichet J; Klener J; Rulseh A; Liscak R; Vojtech Z
Cancer Imaging; 2016 Nov; 16(1):40. PubMed ID: 27894359
[TBL] [Abstract][Full Text] [Related]
6. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
[TBL] [Abstract][Full Text] [Related]
7. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.
Lemma SA; Pasanen AK; Haapasaari KM; Sippola A; Sormunen R; Soini Y; Jantunen E; Koivunen P; Salokorpi N; Bloigu R; Turpeenniemi-Hujanen T; Kuittinen O
Eur J Haematol; 2016 May; 96(5):492-501. PubMed ID: 26153511
[TBL] [Abstract][Full Text] [Related]
8. Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture.
Kawano N; Ochiai H; Yoshida S; Yamashita K; Shide K; Shimoda H; Hidaka T; Kubuki Y; Katayose K; Toyama T; Kawano H; Matsuoka H; Ishizaki J; Maeda K; Satou S; Yano T; Yamaguchi K; Takenaka K; Shimao Y; Oshima K; Ueda A; Shimoda K
Int J Clin Oncol; 2012 Aug; 17(4):336-40. PubMed ID: 21904968
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of Serum Soluble Interleukin-2 Receptor Levels for Differentiating between PCNSL and SCNSL.
Mitobe Y; Matsuda KI; Sonoda Y
Neurol Med Chir (Tokyo); 2023 Mar; 63(3):111-115. PubMed ID: 36682790
[TBL] [Abstract][Full Text] [Related]
10. A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells.
Brandt A; Matschke J; Fehrle W; von Wenserski L; Bokemeyer C; Illerhaus G; Binder M
Leuk Lymphoma; 2019 Feb; 60(2):334-340. PubMed ID: 30033830
[TBL] [Abstract][Full Text] [Related]
11. Primary central nervous system lymphoma with systemic metastasis: case report and review.
Brown MT; McClendon RE; Gockerman JP
J Neurooncol; 1995; 23(3):207-21. PubMed ID: 7673983
[TBL] [Abstract][Full Text] [Related]
12. Secondary central nervous system lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Int J Hematol; 2006 Aug; 84(2):128-35. PubMed ID: 16926134
[TBL] [Abstract][Full Text] [Related]
13. Imaging features (CT, MRI, MRS, and PET/CT) of primary central nervous system lymphoma in immunocompetent patients.
Cheng G; Zhang J
Neurol Sci; 2019 Mar; 40(3):535-542. PubMed ID: 30580380
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis.
Hollender A; Kvaloy S; Lote K; Nome O; Holte H
Eur J Cancer; 2000 Sep; 36(14):1762-8. PubMed ID: 10974623
[TBL] [Abstract][Full Text] [Related]
15. Treatment of secondary central nervous system involvement in systemic aggressive B cell lymphoma using R-MIADD chemotherapy: a single-center study.
Wu Y; Sun X; Bai X; Qian J; Zhu H; Cui Q; Xing R; Chen Y; Liu Q; Lai W; Li J; Wang Y; Sun S; Ji N; Liu Y
Chin Neurosurg J; 2021 Apr; 7(1):20. PubMed ID: 33795020
[TBL] [Abstract][Full Text] [Related]
16. Atypical radiological findings of primary central nervous system lymphoma.
Lin X; Khan IRA; Seet YHC; Lee HY; Yu WY
Neuroradiology; 2020 Jun; 62(6):669-676. PubMed ID: 32077984
[TBL] [Abstract][Full Text] [Related]
17. MRI patterns in recurrence of primary CNS lymphoma in immunocompetent patients.
Schulte-Altedorneburg G; Heuser L; Pels H
Eur J Radiol; 2012 Sep; 81(9):2380-5. PubMed ID: 21683538
[TBL] [Abstract][Full Text] [Related]
18. Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
Fossard G; Ferlay C; Nicolas-Virelizier E; Rey P; Ducray F; Jouanneau E; Faurie P; Belhabri A; Sunyack MP; Chassagne-Clément C; Thiesse P; Sebban C; Biron P; Blay JY; Ghesquières H
Eur J Cancer; 2017 Feb; 72():12-19. PubMed ID: 28012348
[TBL] [Abstract][Full Text] [Related]
19. Prevention and management of secondary central nervous system lymphoma.
Bobillo S; Khwaja J; Ferreri AJM; Cwynarski K
Haematologica; 2023 Mar; 108(3):673-689. PubMed ID: 36384246
[TBL] [Abstract][Full Text] [Related]
20. Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system.
Baraniskin A; Deckert M; Schulte-Altedorneburg G; Schlegel U; Schroers R
Br J Haematol; 2012 Feb; 156(4):421-32. PubMed ID: 22077417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
